Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class ASSE: 688266

Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management

Jun 13, 2026 · Issued by Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A via Shanghai Stock Exchange

Announcement on Using Partial Temporarily Idle Raised Funds for Cash Management

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A

Zai Lab Receives China NMPA Approval of TIVDAK® (tisotumab vedotin for injection) for the Treatment of Adult Patients with Recurrent or Metastatic Cervical CancerJun 9
Announcement on Voluntary Disclosure of Clinical Data and Latest Progress of ZG005 and ZG006 Released at the 2026 American Society of Clinical Oncology (ASCO) Annual MeetingJun 2
Announcement on Voluntary Disclosure of Phase III Clinical Trial of Recombinant Human Thyrotropin β for Injection Reaching Prespecified Primary EndpointMay 8
Announcement on Change of Accounting PoliciesApr 29

All Suzhou Zelgen Biopharmaceuticals Co. Ltd. Class A news releases